biote Corp.

Q3 FY2026 EarningsQ3 FY26 results missed consensus on the top-line but slightly beat on normalized profitability: revenue of $43.3M vs. $44.0M expected, while normalized EPS was $0.05 vs. $0.04 consensus. A voluntary product recall at the Asteria Health facility negatively impacted procedure revenue by ~$5M and drove higher sourcing costs from third-party suppliers. Despite the top-line miss, Biote achieved a 67.69% gross margin, slightly exceeding the 67.53% consensus, supported by favorable pricing in the supplements business. Notably, the company faced non-compliance with debt covenants as of September 30, requiring a subsequent waiver and amendment with Truist Bank.